Abstracts tagged "Biomarkers"

Abstract Number: 1937 • 2015 ACR/ARHP Annual Meeting
Dalazatide (ShK-186), a First-in-Class Blocker of Kv1.3 Potassium Channel on Effector Memory T Cells: Safety, Tolerability and Proof of Concept of Immunomodulation in Patients with Active Plaque Psoriasis
Ernesto J. Munoz-Elias¹, David Peckham¹, Kayla Norton¹, Judilyn Duculan², Inna Cueto², Xuan Li³, James Qin⁴, Kurt Lustig⁵, Eric Tarcha¹, Jared Odegard⁴, James G. Krueger² and Shawn P. Iadonato¹, ¹Kineta Inc, Seattle, WA, ²Rockefeller University, New York, NY, ³Rockefeller University, New York, WA, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Kineta Inc., Seattle, WA
Background/Purpose: Effector memory T cells of both CD4 and CD8 lineages are key drivers of autoimmunity and are pathogenic in several autoimmune diseases including psoriasis,…
Abstract Number: 2601 • 2015 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score in a TNF Inhibitor Tapering Study in Rheumatoid Arthritis Patients: Predictive Value for Successful Tapering, Flaring and Radiographic Progression
Chantal A.M. Bouman¹, Aatke van der Maas¹, Noortje van Herwaarden¹, Eric H. Sasso², Frank H.J. van den Hoogen¹ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: We evaluated the predictive value of the multi-biomarker disease activity (MBDA) score for clinical outcomes and radiographic progression in a TNFi tapering study in…
Abstract Number: 2990 • 2015 ACR/ARHP Annual Meeting
Assessment of NT-Pro BNP As a Potential Marker for Pulmonary Hypertension in Systemic Sclerosis: Data from a Large, Prospective and Unselected Patient Cohort
Anna-Maria Hoffmann-Vold^1,2, Oyvind Midtvedt¹, Torhild Garen³, May Brit Lund⁴, Arne Andreassen⁵ and Øyvind Molberg⁶, ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²Institute of clinical medicine, University of Oslo, Oslo, Norway, ³Rheumatology, Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Respiratory Diseases, Oslo University Hospital, Oslo, Norway, ⁵Cardiology, Oslo University Hospital, Oslo, Norway, ⁶Department of Rheumatology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway
Background/Purpose: In Systemic Sclerosis (SSc), pulmonary arterial hypertension (PAH) is often diagnosed at an advanced stage. Serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are…
Abstract Number: 217 • 2015 ACR/ARHP Annual Meeting
Circulating Levels of Neo-Epitopes Reflecting Connective Tissue Turnover As Biomarkers of Gout and Frequent Gout Attacks in Men
Ana Valdes¹, Tina Manon-Jensen², Wendy Jenkins³, Anne Sofie Siebuhr⁴, Morten Asser Karsdal⁴, Sally Doherty⁵, Abhishek Abhishek³, Helen Richardson³, Weiya Zhang⁶, Michael Doherty⁷ and Anne C. Bay-Jensen⁸, ¹Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham, Nottingham, United Kingdom, ²Antibody Research Unit, Nordic Bioscience, 2370, Denmark, ³Devision of Rheumatology, University of Nottingham, NG5 1PB, England, ⁴Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁵Division of ROD, University of Nottingham, Nottingham, United Kingdom, ⁶Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ⁷Academic Rheumatology, City Hospital, Nottingham, United Kingdom, ⁸Biomarkers and Research, Rheumatology, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Recurrent flares constitute the main clinical burden of gout. The neo-epitope blood-based biomarkers, C1M and C3M, measuring matrix metalloproteinases (MMP)-mediated connective tissue degradation, have previously…
Abstract Number: 597 • 2015 ACR/ARHP Annual Meeting
JAK Inhibition Significantly Reduced Fibrogenesis in Rheumatoid Arthritis Patients
Shintaro Hirata¹, Natasja Stæhr Gudman², Kentaro Hanami¹, Satoshi Kubo¹, Anne C. Bay-Jensen², Morten Asser Karsdal³ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Connective tissue degradation and formation is markedly increased in rheumatoid arthritis (RA). Increased tissue formation may result in fibrosis, whereas increased degradation may result…
Abstract Number: 1077 • 2015 ACR/ARHP Annual Meeting
High Levels of CCL-18 Are Associated with Deterioration of Lung Function, Increased Annual Fibrosis Progression Rate and Decreased Survival in Systemic Sclerosis
Anna-Maria Hoffmann-Vold^1,2, Anders Heiervang Tennøe², Oyvind Midtvedt¹, Torhild Garen³, May Brit Lund⁴, Trond Mogens Aalokken⁵, Cathrine Brunborg⁶, Thor Ueland² and Øyvind Molberg⁷, ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²Institute of clinical medicine, University of Oslo, Oslo, Norway, ³Rheumatology, Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Respiratory Diseases, Oslo University Hospital, Oslo, Norway, ⁵Radiology, Oslo University Hospital, Oslo, Norway, ⁶Biostatistics, Epidemiology and Health Economics, Oslo University Hospital, Oslo, Norway, ⁷Department of Rheumatology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD), but biomarkers for individual risk stratification are largely missing. There is an…
Abstract Number: 1661 • 2015 ACR/ARHP Annual Meeting
Translational Data and Phase 1 Study Results of a New Monoclonal Antibody Targeting Toll like Receptor 4 (TLR4) Developed for Rheumatoid Arthritis (RA) Treatment with a Potential for Personalized Medicine
Emmanuel Monnet¹, Limin Shang¹, Geneviève Lapeyre¹, Kathy De Graaf², Eric Hatterer¹, Gaelle Wambiekele¹, Walter Ferlin¹, Philippe Jacqmin³, Cem Gabay⁴, Jeremy Sokolove⁵, Simon Jones⁶, Ernest H. Choy⁷, Iain B. McInnes⁸, Marie Kosco-Vilbois¹ and Cristina De Min¹, ¹NovImmune S.A., Geneva, Switzerland, ²Novimmune S.A., Geneva, Switzerland, ³SGS Exprimo, Mechelen, Belgium, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁶Cardiff Institute of Infection & Immunity, Cardiff, United Kingdom, ⁷Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ⁸Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Innate immunity is implicated in RA pathogenesis and is likely mediated via TLR pathways, with anti-citrullinated protein antibodies (ACPA) serving as key triggers. NI-0101…
Abstract Number: 1965 • 2015 ACR/ARHP Annual Meeting
T Cell Activation, Proliferation and Differentiation Markers Lack Diagnostic Accuracy for Detecting Active GCA and PMR
Kornelis S.M. van der Geest¹, Wayel H. Abdulahad², Qi Wang², Mirjam Roffel², Gerda Horst², Abraham Rutgers², Annemieke M.H. Boots² and Elisabeth Brouwer², ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: The most important biomarker in GCA and PMR patients is increased erythrocytes sedimentation rate (ESR) and/ or increased serum level of C-reactive protein (CRP).…
Abstract Number: 2606 • 2015 ACR/ARHP Annual Meeting
Serum Myeloid Related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate in DMARD Naïve Patients
Pradeepta Sekhar Patro, Ankita Singh, Ramnath Misra and Amita Aggarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: MRP8/14 are calcium binding proteins produced by myeloid cells. Recently baseline serum levels of MRP8/14 have been shown to predict response to biologicals in…
Abstract Number: 2994 • 2015 ACR/ARHP Annual Meeting
The Global Microrna Profile of Systemic Sclerosis Whole Skin/Dermal Fibroblasts and the Role of the Xq26.3 miRNA Cluster As a TGF-b Pathway Positive Feedback Mechanism
Gloria Salazar¹, John Hagan², Minghua Wu³, Xinjian Guo⁴, Xiaodong Zhou⁴, Julio Charles¹, Maureen D Mayes¹ and Shervin Assassi¹, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²Neurosurgery, University of Texas at Houston, Houston, TX, ³Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁴Internal Medicine, University of Texas Medical School at Houston, Houston, TX
Background/Purpose: MicroRNA (miRNA) are critical gene regulators that frequently play central roles in disease. Here, we report the miRNA expression signatures of systemic sclerosis (SSc)…
Abstract Number: 289 • 2015 ACR/ARHP Annual Meeting
Evaluation of Usefulness of Krebs Von Den Lungen-6 As a Biomarker of Interstitial Lung Disease with Polymyositis and Dermatomyositis Including in the Short Time Course after Treatment
Masanori Hanaoka, Yasuhiro Katsumata, Yasushi Kawaguchi, Hidenaga Kawasumi, Hisae Terajima-Ichida, Kae Takagi, Akiko Tochimoto, Yuki Ichimura and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Because of the extremely variable incidence and outcome of interstitial lung disease (ILD) in polymyositis/dermatomyositis (PM/DM), explorationand validation of biomarkers for diagnosis, prognosis, and response…
Abstract Number: 603 • 2015 ACR/ARHP Annual Meeting
Which Seronegative RA Patients Respond to Rituximab? – Preliminary Analysis of a Merged Clinical Trials Dataset
Elizabeth M.A. Hensor^1,2, Edward M. Vital^1,2 and Paul Emery^1,2, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Seronegative RA patients have inferior clinical response to rituximab [1]. However, there is significant heterogeneity in this group of patients for baseline clinical features…
Abstract Number: 1078 • 2015 ACR/ARHP Annual Meeting
CXCL4 Does Not Predict Extent or Progression of Interstitial Lung Disease in Systemic Sclerosis
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Michael Roth¹, Chi-hong Tseng¹, Holly LeClair², Philip J. Clements¹, Daniel E. Furst³, Maureen D Mayes⁴, Julio Charles⁵, Dinesh Khanna⁶, Robert Elashoff⁷, Shervin Assassi⁸ and Scleroderma Lung Study II Group, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of Texas - Houston Medical School, Houston, TX, ⁵Internal Medicine/Rheumatology, University of Texas - Houston Medical School, Houston, TX, ⁶University of Michigan, Ann Arbor, MI, ⁷Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁸Rheumatology, University of Texas Medical School at Houston, Houston, TX
Background/Purpose: Increased circulatory levels of the chemokine CXCL4 have been associated with the presence of pulmonary fibrosis (PF) by HRCT in an observational study of…
Abstract Number: 1666 • 2015 ACR/ARHP Annual Meeting
Mitochondrial Haplogroups in Patients with Rheumatoid Arthritis with Respect to Biological Treatment
Pernille Hurup Duhn¹, Jacob Sode^2,3,4, Christian Hagen⁵, Michael Christiansen^5,6 and Henning Locht⁴, ¹Department of Rheumatology, Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark, ²Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ³Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark, ⁴Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ⁵Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Copenhagen, Denmark, ⁶Department of Biomedical Sciences, Faculty of Health and Life Science, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Throughout evolution mutations in mitochondrial DNA (mtDNA) have accumulated sequentially subdividing the human population into different haplogroups classificed from A-Z. Specific mtDNA haplogroups have…
Abstract Number: 1992 • 2015 ACR/ARHP Annual Meeting
Plasma Endothelin-1 Parallels the Vasoconstriction Phase in Reversible Cerebral Vasoconstriction Syndrome
Seby John¹, Leonard H. Calabrese², Juan J. Maya³, Alex Massiello⁴, Ken Uchino¹, Serpil Erzurum⁵, Allison Janocha⁵ and Rula A Hajj-Ali⁶, ¹Cerebrovascular Center, Cleveland Clinic Foundation, Cleveland, OH, ²Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ³Internal Medicine, Cleveland Clinic, Cleveland, OH, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH, ⁵Cleveland Clinic, Cleveland, OH, ⁶Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Plasma Endothelin-1 parallels the vasoconstriction phase in Reversible Cerebral Vasoconstriction SyndromeBackground/Purpose: Cerebral vasoconstriction is thought to be the underlying pathogenetic mechanism of Reversible Cerebral Vasoconstriction…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].